GAREM2

Summary

GAREM2 (GRB2 associated regulator of MAPK1 subtype 2, HGNC:27172) is a protein-coding gene on chromosome 2p23.3, encoding GRB2-associated and regulator of MAPK protein 2 (Q75VX8). Probable adapter protein that may provide a link between cell surface epidermal growth factor receptor and the MAPK/ERK signaling pathway.

Predicted to act upstream of or within several processes, including cognition; neuron projection extension; and social behavior.

Source: NCBI Gene 150946 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 426 total — 32 pathogenic, 43 likely-pathogenic
• MANE Select transcript: NM_001168241

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27172
Approved symbol	GAREM2
Name	GRB2 associated regulator of MAPK1 subtype 2
Location	2p23.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA2038, FLJ00375
Ensembl gene	ENSG00000157833
Ensembl biotype	protein_coding
OMIM	617999
Entrez	150946

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000401533, ENST00000407684, ENST00000496070

RefSeq mRNA: 2 — MANE Select: NM_001168241 NM_001168241, NM_001191033

CCDS: CCDS54336, CCDS54337

Canonical transcript exons

ENST00000401533 — 6 exons

Exon	Start	End
ENSE00000730265	26186189	26186358
ENSE00001035337	26184233	26185276
ENSE00001035341	26182967	26183097
ENSE00001485856	26187231	26189663
ENSE00001485865	26176344	26176484
ENSE00001485869	26173088	26173332

Expression profiles

Bgee: expression breadth ubiquitous, 187 present calls, max score 95.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.1852 / max 54.6453, expressed in 1333 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
19251	2.2393	503
19253	2.1823	944
19252	1.7636	826

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	95.59	gold quality
ganglionic eminence	UBERON:0004023	91.80	gold quality
caudate nucleus	UBERON:0001873	84.61	gold quality
amygdala	UBERON:0001876	84.43	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.06	gold quality
putamen	UBERON:0001874	83.61	gold quality
hypothalamus	UBERON:0001898	83.39	gold quality
nucleus accumbens	UBERON:0001882	83.21	gold quality
medial globus pallidus	UBERON:0002477	82.94	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	82.48	gold quality
secondary oocyte	CL:0000655	82.39	gold quality
anterior cingulate cortex	UBERON:0009835	82.36	gold quality
oocyte	CL:0000023	82.10	gold quality
right frontal lobe	UBERON:0002810	82.03	gold quality
substantia nigra	UBERON:0002038	81.28	gold quality
spinal cord	UBERON:0002240	80.91	gold quality
cortical plate	UBERON:0005343	80.24	gold quality
temporal lobe	UBERON:0001871	80.12	gold quality
globus pallidus	UBERON:0001875	79.38	gold quality
midbrain	UBERON:0001891	79.28	gold quality
neocortex	UBERON:0001950	79.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	78.80	gold quality
Ammon’s horn	UBERON:0001954	78.71	gold quality
cerebral cortex	UBERON:0000956	78.62	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	78.58	gold quality
forebrain	UBERON:0001890	78.51	gold quality
frontal cortex	UBERON:0001870	78.29	gold quality
prefrontal cortex	UBERON:0000451	78.15	gold quality
stromal cell of endometrium	CL:0002255	77.54	gold quality
brain	UBERON:0000955	77.48	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

59 targeting GAREM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-2276-3P	98.76	67.75	1384
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-6818-3P	98.56	68.23	1307
HSA-MIR-6776-5P	98.54	67.43	1304

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	gareml	ENSDARG00000073933
mus_musculus	Garem2	ENSMUSG00000044576
rattus_norvegicus	Garem2	ENSRNOG00000048004

Paralogs (1): GAREM1 (ENSG00000141441)

Protein

Protein identifiers

GRB2-associated and regulator of MAPK protein 2 — Q75VX8 (reviewed: Q75VX8)

Alternative names: GRB2-associated and regulator of MAPK1-like

All UniProt accessions (1): Q75VX8

UniProt curated annotations — full annotation on UniProt →

Function. Probable adapter protein that may provide a link between cell surface epidermal growth factor receptor and the MAPK/ERK signaling pathway.

Similarity. Belongs to the GAREM family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q75VX8-1	1	yes
Q75VX8-2	2
Q75VX8-3	3

RefSeq proteins (2): NP_001161713, NP_001177962 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR025946	CABIT_dom	Domain
IPR052281	GAREM	Family

Pfam: PF12736

UniProt features (23 total): compositionally biased region 6, region of interest 6, sequence conflict 5, splice variant 3, chain 1, domain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q75VX8-F1	61.81	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 735

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 65 (showing top): GOBP_COGNITION, GOBP_BEHAVIOR, GOBP_NEURON_PROJECTION_EXTENSION, GOBP_GROWTH, GOBP_NEUROGENESIS, GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_INTRASPECIES_INTERACTION_BETWEEN_ORGANISMS, GOBP_DEVELOPMENTAL_CELL_GROWTH, GOBP_CELL_PROJECTION_ORGANIZATION, GOBP_DEVELOPMENTAL_GROWTH_INVOLVED_IN_MORPHOGENESIS, GOBP_CELL_GROWTH, GEORGES_TARGETS_OF_MIR192_AND_MIR215, GOBP_DEVELOPMENTAL_GROWTH, GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN, PLASARI_TGFB1_TARGETS_10HR_UP, E2F5_TARGET_GENES

GO Biological Process (4): response to stress (GO:0006950), social behavior (GO:0035176), cognition (GO:0050890), neuron projection extension (GO:1990138)

GO Molecular Function (0):

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to stimulus	1
behavior	1
biological process involved in intraspecies interaction between organisms	1
nervous system process	1
developmental cell growth	1
neuron projection morphogenesis	1
developmental growth involved in morphogenesis	1

Protein interactions and networks

STRING

632 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GAREM2	FAM24A	A6NFZ4	511
GAREM2	THEMIS2	Q5TEJ8	475
GAREM2	ZNF562	Q6V9R5	434
GAREM2	PM20D1	Q6GTS8	373
GAREM2	MAB21L3	Q8N8X9	372
GAREM2	KLHL35	Q6PF15	355
GAREM2	FAM53A	Q6NSI3	349
GAREM2	TTC23	Q5W5X9	348
GAREM2	RNF182	Q8N6D2	324
GAREM2	OR2L13	Q8N349	309
GAREM2	CWC25	Q9NXE8	308
GAREM2	PIGZ	Q86VD9	304
GAREM2	MVB12A	Q96EY5	303
GAREM2	UMODL1	Q5DID0	300
GAREM2	SPATA19	Q7Z5L4	296

IntAct

8 interactions, top by confidence:

A	B	Type	Score
GRB2	WIPF3	psi-mi:“MI:0914”(association)	0.730
GRB2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
SYNGAP1	POM121C	psi-mi:“MI:0914”(association)	0.350
GAREM1	TNKS	psi-mi:“MI:0914”(association)	0.350
GAREM1	SCGB1D2	psi-mi:“MI:0914”(association)	0.350

BioGRID (27): GAREML (Affinity Capture-MS), GRB2 (Affinity Capture-Western), PTPN11 (Affinity Capture-Western), GAREML (Affinity Capture-MS), GAREML (Affinity Capture-MS), GAREML (Affinity Capture-MS), GAREML (Affinity Capture-MS), GAREML (Affinity Capture-RNA), GAREML (Affinity Capture-MS), GAREML (Proximity Label-MS), GAREML (Proximity Label-MS), GAREML (Proximity Label-MS), GAREML (Proximity Label-MS), GAREML (Proximity Label-MS), GAREML (Proximity Label-MS)

ESM2 similar proteins: A0A0U1RQ45, A0A1B0GWB2, A2A9T0, A6QPA0, A7MCY6, D3ZFB6, E9PUL5, E9Q0B3, F5GYI3, F5H4A9, J3QNX5, O70142, P0C1G7, P81408, P97764, P98077, Q148V8, Q15654, Q2KI80, Q3SX26, Q3SZL6, Q4V9L6, Q5FVJ4, Q5FW56, Q5RAC1, Q5T7N3, Q6DG50, Q6PAJ3, Q6PJ61, Q6ZMQ8, Q6ZNR0, Q6ZRV2, Q75VX8, Q7Z6L0, Q86UK7, Q86VE0, Q8BGW2, Q8BRJ3, Q8BX43, Q8C0R7

Diamond homologs: Q3UFT3, Q6NRE4, Q6PAJ3, Q75VX8, Q7ZVU1, Q9H706

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

426 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	32
Likely pathogenic	43
Uncertain significance	126
Likely benign	149
Benign	27

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1069908	NM_000182.5(HADHA):c.1523del (p.Leu508fs)	Pathogenic
1073572	NM_000182.5(HADHA):c.1319dup (p.Ala441fs)	Pathogenic
1075355	NM_000182.5(HADHA):c.1528G>T (p.Glu510Ter)	Pathogenic
1386792	NM_000182.5(HADHA):c.1654dup (p.Ala552fs)	Pathogenic
1390752	NM_000182.5(HADHA):c.2200A>T (p.Lys734Ter)	Pathogenic
1455936	NM_000182.5(HADHA):c.1491_1495dup (p.Tyr499fs)	Pathogenic
1459829	NM_000182.5(HADHA):c.1540del (p.Thr514fs)	Pathogenic
188712	NM_000182.5(HADHA):c.1967del (p.Ile655_Leu656insTer)	Pathogenic
194808	NM_000182.5(HADHA):c.1918C>T (p.Gln640Ter)	Pathogenic
194917	NM_000182.5(HADHA):c.2146+1G>A	Pathogenic
2020384	NM_000182.5(HADHA):c.2010del (p.Asp670fs)	Pathogenic
2025539	NC_000002.12:g.26201318_26201321del	Pathogenic
2101164	NM_000182.5(HADHA):c.2231del (p.Phe744fs)	Pathogenic
2675968	NM_000182.5(HADHA):c.1533dup (p.Ile512fs)	Pathogenic
2921383	NM_000182.5(HADHA):c.2011del (p.Glu671fs)	Pathogenic
2922371	NM_000182.5(HADHA):c.1361_1364dup (p.Lys455delinsAsnTer)	Pathogenic
2934638	NM_000182.5(HADHA):c.1231_1235del (p.Lys411fs)	Pathogenic
2941242	NM_000182.5(HADHA):c.2039_2040dup (p.Phe681fs)	Pathogenic
2942406	NM_000182.5(HADHA):c.1183dup (p.Thr395fs)	Pathogenic
2943817	NM_000182.5(HADHA):c.2063_2087dup (p.Glu699fs)	Pathogenic
2947613	NM_000182.5(HADHA):c.1249del (p.Ala416_Leu417insTer)	Pathogenic
2950171	NM_000182.5(HADHA):c.1921del (p.Glu641fs)	Pathogenic
371597	NM_000182.5(HADHA):c.1915_1918del (p.Tyr639fs)	Pathogenic
3754541	NM_000182.5(HADHA):c.1889del (p.Arg630fs)	Pathogenic
4081703	NM_000182.5(HADHA):c.1249_1259del (p.Ala416_Leu417insTer)	Pathogenic
432660	NM_000182.5(HADHA):c.1427_1428del (p.Thr476fs)	Pathogenic
4784257	NM_000182.5(HADHA):c.1586dup (p.Leu530fs)	Pathogenic
801655	NM_000182.5(HADHA):c.1689+2T>G	Pathogenic
848128	NM_000182.5(HADHA):c.1690-17_1690-2del	Pathogenic
8729	NM_000182.5(HADHA):c.1132C>T (p.Gln378Ter)	Pathogenic

SpliceAI

1212 predictions. Top by Δscore:

Variant	Effect	Δscore
2:26173330:CAG:C	donor_loss	1.0000
2:26173331:AGG:A	donor_loss	1.0000
2:26173332:GGT:G	donor_loss	1.0000
2:26173333:G:GA	donor_loss	1.0000
2:26173334:T:G	donor_loss	1.0000
2:26176342:A:AC	acceptor_loss	1.0000
2:26176342:A:AG	acceptor_gain	1.0000
2:26176342:AG:A	acceptor_gain	1.0000
2:26176342:AGG:A	acceptor_gain	1.0000
2:26176343:G:GG	acceptor_gain	1.0000
2:26176343:GG:G	acceptor_gain	1.0000
2:26176343:GGG:G	acceptor_gain	1.0000
2:26176343:GGGGA:G	acceptor_gain	1.0000
2:26176484:GGTG:G	donor_loss	1.0000
2:26176485:GT:G	donor_loss	1.0000
2:26176486:T:A	donor_loss	1.0000
2:26182962:TGCA:T	acceptor_loss	1.0000
2:26182964:CA:C	acceptor_loss	1.0000
2:26182965:A:AT	acceptor_loss	1.0000
2:26182966:GGGAA:G	acceptor_gain	1.0000
2:26183095:AAG:A	donor_loss	1.0000
2:26183096:AG:A	donor_loss	1.0000
2:26183097:GG:G	donor_loss	1.0000
2:26183099:T:G	donor_loss	1.0000
2:26188064:T:TA	acceptor_gain	1.0000
2:26176323:T:TA	acceptor_gain	0.9900
2:26176342:AGGG:A	acceptor_gain	0.9900
2:26176343:GGGG:G	acceptor_gain	0.9900
2:26176480:CCCAG:C	donor_gain	0.9900
2:26182961:AT:A	acceptor_gain	0.9900

AlphaMissense

5557 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:26176383:T:C	L51P	1.000
2:26176403:T:A	W58R	1.000
2:26176403:T:C	W58R	1.000
2:26176419:C:A	A63D	1.000
2:26176428:T:C	L66P	1.000
2:26176446:T:A	V72D	1.000
2:26176449:T:A	I73N	1.000
2:26176451:G:A	G74R	1.000
2:26176451:G:C	G74R	1.000
2:26176451:G:T	G74W	1.000
2:26176452:G:A	G74E	1.000
2:26176452:G:T	G74V	1.000
2:26176467:T:A	I79N	1.000
2:26176467:T:G	I79S	1.000
2:26182972:T:C	F87L	1.000
2:26182973:T:C	F87S	1.000
2:26182973:T:G	F87C	1.000
2:26182974:C:A	F87L	1.000
2:26182974:C:G	F87L	1.000
2:26184282:T:C	L145P	1.000
2:26184300:T:A	L151H	1.000
2:26184300:T:C	L151P	1.000
2:26184491:T:C	C215R	1.000
2:26184495:T:A	L216H	1.000
2:26184495:T:C	L216P	1.000
2:26184500:T:C	C218R	1.000
2:26184502:C:G	C218W	1.000
2:26184534:T:A	L229Q	1.000
2:26184534:T:C	L229P	1.000
2:26184557:T:C	F237L	1.000

dbSNP variants (sampled 300 via entrez): RS1000037528 (2:26193496 C>T), RS1000056377 (2:26197949 C>T), RS1000185624 (2:26190517 C>T), RS1000272229 (2:26190360 T>A,C), RS1000297620 (2:26192008 G>A,T), RS1000426259 (2:26178890 G>GGAGGCGGAGGCGGAGGCA), RS1000475423 (2:26195956 C>T), RS1000567035 (2:26203173 G>A), RS1000578393 (2:26202820 A>G), RS1000758791 (2:26183799 C>A,G,T), RS1000969850 (2:26172622 C>A,G,T), RS1000980828 (2:26171623 G>A,C), RS1001105832 (2:26172010 C>A,G,T), RS1001167089 (2:26178011 G>A), RS1001192623 (2:26184169 G>A)

Disease associations

OMIM: gene MIM:617999 | disease phenotypes: MIM:609015, MIM:609016, MIM:614728

GenCC curated gene-disease

Mondo (5): metabolic disease (MONDO:0005066), mitochondrial trifunctional protein deficiency (MONDO:0012172), long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (MONDO:0012173), mitochondrial trifunctional protein deficiency 1 (MONDO:0958181), Seckel syndrome 6 (MONDO:0013871)

Orphanet (2): Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (Orphanet:5), Mitochondrial trifunctional protein deficiency (Orphanet:746)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008659	Metabolic Diseases	C18.452
C566945	Trifunctional Protein Deficiency With Myopathy And Neuropathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	2
Estradiol	increases expression, affects cotreatment	2
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Methotrexate	increases expression	1
Thimerosal	decreases expression	1
Urethane	decreases expression	1
Aflatoxin B1	increases expression	1
Cadmium Chloride	increases expression	1
Acrylamide	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00192621	PHASE4	COMPLETED	Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
NCT01443806	PHASE4	COMPLETED	Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand
NCT02645279	PHASE4	UNKNOWN	Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates
NCT04653779	PHASE4	UNKNOWN	A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
NCT05084079	PHASE4	UNKNOWN	Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT
NCT05855577	PHASE4	NOT_YET_RECRUITING	Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson’s Patients
NCT06003153	PHASE4	RECRUITING	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT06009653	PHASE4	WITHDRAWN	Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
NCT00387114	PHASE3	TERMINATED	Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study
NCT00546052	PHASE3	COMPLETED	A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
NCT00607373	PHASE3	COMPLETED	Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
NCT00694109	PHASE3	COMPLETED	An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
NCT00935766	PHASE3	TERMINATED	Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
NCT01286909	PHASE3	UNKNOWN	Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
NCT01343680	PHASE3	TERMINATED	Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
NCT04371978	PHASE3	TERMINATED	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
NCT04809220	PHASE3	COMPLETED	A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
NCT05260021	PHASE3	COMPLETED	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
NCT05425745	PHASE3	COMPLETED	Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
NCT05505994	PHASE3	UNKNOWN	The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
NCT05691712	PHASE3	COMPLETED	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
NCT06568471	PHASE3	RECRUITING	A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06672237	PHASE3	RECRUITING	A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT07613307	PHASE3	NOT_YET_RECRUITING	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
NCT00001723	PHASE2	COMPLETED	Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
NCT00119379	PHASE2	COMPLETED	Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
NCT00362180	PHASE2	COMPLETED	Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
NCT00446264	PHASE2	COMPLETED	Islet Allotransplantation With Steroid Free Immunosuppression
NCT00477594	PHASE2	COMPLETED	Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
NCT00622765	PHASE2	COMPLETED	A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
NCT00707746	PHASE2	COMPLETED	Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
NCT01041677	PHASE2	COMPLETED	A Study of the Safety of R256918 in Obese Patients
NCT01135537	PHASE2	TERMINATED	Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
NCT01596699	PHASE2	TERMINATED	Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
NCT01927913	PHASE2	WITHDRAWN	Treatment of Iron Overload Requiring Chelation Therapy
NCT01968720	PHASE2	COMPLETED	Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
NCT02019667	PHASE2	COMPLETED	Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
NCT02102737	PHASE2	COMPLETED	Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique
NCT02512679	PHASE2	TERMINATED	Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
NCT02587572	PHASE2	WITHDRAWN	Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial